REC: CardioClinics最新文献_第3页

Introducción

REC: CardioClinics Pub Date : 2024-12-01 DOI: 10.1016/j.rccl.2024.09.004

Cristina Lozano-Granero , Pablo Díez-Villanueva

引用次数: 0

V CardioMIR: el Congreso de los Jóvenes Cardiólogos

REC: CardioClinics Pub Date : 2024-12-01 DOI: 10.1016/j.rccl.2024.10.008

Eva Moreno Monterde , Amadeo Wals Rodríguez , Olga Durán Bobin , Ana Laffond

引用次数: 0

Diagnostic accuracy of anatomic vs functional tests for coronary artery disease in patients with left bundle branch block and right ventricular pacing 左束支传导阻滞和右心室起搏患者冠状动脉疾病的解剖检验与功能检验的诊断准确性比较

REC: CardioClinics Pub Date : 2024-10-01 DOI: 10.1016/j.rccl.2024.03.002

{"title":"Diagnostic accuracy of anatomic vs functional tests for coronary artery disease in patients with left bundle branch block and right ventricular pacing","authors":"","doi":"10.1016/j.rccl.2024.03.002","DOIUrl":"10.1016/j.rccl.2024.03.002","url":null,"abstract":"<div><h3>Introduction and objectives</h3><div>A lower accuracy of functional tests for the diagnosis of significant coronary disease in patients with left bundle branch block (LBBB) has been described, due to a greater number of false positives. The aim of this study was to evaluate whether an anatomic test such as computerized tomography coronary angiogram (CTCA) outperforms SPECT myocardial perfusion imaging (SPECT-MPI) or dobutamine stress echocardiography (DSE) in the diagnosis of significant coronary artery disease in patients with LBBB and right ventricular pacing.</div></div><div><h3>Methods</h3><div>Observational study of 149 patients with LBBB and right ventricular pacing referred to SPECT-MPI, DSE or CTCA at three centers. Diagnostic performance (predictive accuracy, sensitivity, specificity, positive and negative predictive value) was evaluated using coronary angiography as the benchmark.</div></div><div><h3>Results</h3><div>The study included 77 patients who underwent SPECT-MPI, 39 who performed DSE and 33 who performed CTCA. The prevalence of obstructive coronary disease was similar in the three cohorts, with a higher rate of abnormal results on SPECT-MPI (84% vs 64% vs 61%; <em>P</em>  =.006). DSE and CTCA showed a similar rate of abnormal results, as well as similar predictive accuracy (64% vs 67%; <em>P</em>  <!-->.999).</div></div><div><h3>Conclusions</h3><div>In patients with LBBB and right ventricular pacing, DSE and CTCA had similar accuracy and performed better than SPECT-MPI for the diagnosis of significant coronary artery disease.</div></div>","PeriodicalId":36870,"journal":{"name":"REC: CardioClinics","volume":"59 4","pages":"Pages 295-302"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140766134","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Non-invasive multiparametric assessment of intracardiac tumor 心内肿瘤的无创多参数评估

REC: CardioClinics Pub Date : 2024-10-01 DOI: 10.1016/j.rccl.2024.01.007

引用次数: 0

¿Es el policomprimido CNIC la solución para mejorar la adherencia terapéutica de los pacientes con síndrome coronario agudo? CNIC 多药丸是改善急性冠状动脉综合征患者治疗依从性的解决方案吗？

REC: CardioClinics Pub Date : 2024-10-01 DOI: 10.1016/j.rccl.2024.07.003

Ana Viana Tejedor , Cosme García García , Rut Andrea Riba

引用次数: 0

Underuse of systemic thrombolysis in pulmonary embolism: A single center retrospective observational study 肺栓塞患者全身溶栓治疗使用不足：单中心回顾性观察研究

REC: CardioClinics Pub Date : 2024-10-01 DOI: 10.1016/j.rccl.2024.03.006

{"title":"Underuse of systemic thrombolysis in pulmonary embolism: A single center retrospective observational study","authors":"","doi":"10.1016/j.rccl.2024.03.006","DOIUrl":"10.1016/j.rccl.2024.03.006","url":null,"abstract":"<div><h3>Introduction and objectives</h3><div>Acute pulmonary embolism (PE) is the third most frequent acute cardiovascular syndrome. Systemic thrombolysis is the treatment of choice in patients with high-risk PE. The aim of this study is to analyze the patients diagnosed with pulmonary embolism at the emergency department, acute treatment decisions and the main outcomes.</div></div><div><h3>Methods</h3><div>A single-center retrospective observational study was conducted in patients with the diagnosis of PE at the emergency department over a period of 3 years, followed by a one-year period of follow-up. Reported <em>P</em> values below .05 indicate statistical significance.</div></div><div><h3>Results</h3><div>A total of 240 patients presented the diagnosis of PE, with a mean age of 69.2 (± 17.4) years. Nearly a third of patients were classified with high or intermediate-high risk PE, but systemic thrombolysis was only performed in nine patients (3.8%). Among the high-risk PE subgroup, age (<em>P</em>  =.54) and the existence of absolute and/or relative contraindications for thrombolysis (<em>P</em>  <!-->.99) were not predictors of the decision of non-revascularization. At the end of the follow-up period, 23.9% of the patients reported persisting symptoms, and chronic thromboembolic pulmonary hypertension was documented in 12.8% of the patients.</div></div><div><h3>Conclusions</h3><div>Acute treatment of pulmonary embolism is imperative to reduce mortality and prevent long-term sequelae. Systemic thrombolysis is the first line therapy in high-risk patients, but it is underused by medical population even in the absence of formal contraindications. It is necessary a new national-level model of actuation, implementing alternative strategies such as interventional ones to improve outcomes.</div></div>","PeriodicalId":36870,"journal":{"name":"REC: CardioClinics","volume":"59 4","pages":"Pages 278-284"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140761644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Infrautilización del tratamiento de reperfusión en la embolia pulmonar: la capacidad para el cambio 肺栓塞再灌注疗法利用不足：改变的能力

REC: CardioClinics Pub Date : 2024-10-01 DOI: 10.1016/j.rccl.2024.07.007

Pablo Salinas

引用次数: 0

Uso de nuevas terapias hipolipemiantes en la práctica clínica. Consenso SEC/SEA/SEEN/SEMFYC/SEMERGEN/SEMG/SEN/SEACV/S.E.N. 在临床实践中使用新型降脂疗法。SEC/SEA/SEEN/SEMFYC/SEMERGEN/SEMG/SEN/SEACV/S.E.N.共识。

REC: CardioClinics Pub Date : 2024-10-01 DOI: 10.1016/j.rccl.2024.06.002

David Vivas , Carlos Escobar , Alberto Cordero , Rosa Fernández-Olmo , Armando Oterino , Agustín Blanco-Echevarría , Manuel Botana , Daniel Escribano , María del Mar Freijo , Pedro Martínez-Losas , Vicente Pascual , Borja Quiroga , Carmen Sánchez-Peinador , Mónica Torres-Fonseca , Román Freixa-Pamias , Vivencio Barrios , Gonzalo Barón-Esquivias

{"title":"Uso de nuevas terapias hipolipemiantes en la práctica clínica. Consenso SEC/SEA/SEEN/SEMFYC/SEMERGEN/SEMG/SEN/SEACV/S.E.N.","authors":"David Vivas , Carlos Escobar , Alberto Cordero , Rosa Fernández-Olmo , Armando Oterino , Agustín Blanco-Echevarría , Manuel Botana , Daniel Escribano , María del Mar Freijo , Pedro Martínez-Losas , Vicente Pascual , Borja Quiroga , Carmen Sánchez-Peinador , Mónica Torres-Fonseca , Román Freixa-Pamias , Vivencio Barrios , Gonzalo Barón-Esquivias","doi":"10.1016/j.rccl.2024.06.002","DOIUrl":"10.1016/j.rccl.2024.06.002","url":null,"abstract":"<div><div>Although in the last years a better control of vascular risk factors has been achieved, «real-world» data showed that only a few percentage of patients reach low-density lipoprotein-cholesterol goal levels. Recently, new therapies for the management of dyslipidaemias have emerged, and they could help to achieve the goal targets recommended by currents practical clinical guidelines so as to reduce vascular outcomes. Nevertheless, it is still uncertain in daily clinical practice the ideal timing of prescribing these new drugs, and what are the patients more benefited, compared to «classical» therapies such as statins and/or ezetimibe. In this complex scenario, this consensus document is proposed. It is certified by most of the scientific societies of clinical specialties that may play a role in the patient-healthcare process of atherosclerotic disease (SEC/SEA/SEEN/SEMFYC/SEMERGEN/SEMG/SEN/SEACV/S.E.N.), and its aim is to recommend some practical and simple guidelines, based on current scientific evidence, for the management of new therapies for dyslipidaemias in different scenarios of daily clinical practice.</div></div>","PeriodicalId":36870,"journal":{"name":"REC: CardioClinics","volume":"59 4","pages":"Pages 310-321"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141851580","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Characterizing the “iceberg peak” in valvular heart disease: Outcomes and costs of in-hospital procedures in Spain 瓣膜性心脏病 "冰山高峰 "的特征：西班牙院内手术的结果和成本

REC: CardioClinics Pub Date : 2024-10-01 DOI: 10.1016/j.rccl.2024.02.006

{"title":"Characterizing the “iceberg peak” in valvular heart disease: Outcomes and costs of in-hospital procedures in Spain","authors":"","doi":"10.1016/j.rccl.2024.02.006","DOIUrl":"10.1016/j.rccl.2024.02.006","url":null,"abstract":"<div><h3>Introduction and objectives</h3><div>The aim was to describe the burden of disease of valvular heart disease (VHD) in-hospital interventions in Spain.</div></div><div><h3>Methods</h3><div>The analysis involved all cases between 2016 and 2019 in the Spanish Ministry of Health database under the International Classification of Diseases 10th Revision. Procedure rates by region and year (×10<sup>6</sup>), patient risk profile (comorbidities), health outcomes (death), length of stay (LoS), and costs were examined.</div></div><div><h3>Results</h3><div>A total of 57878 procedures were analyzed, representing a national rate from 292 in 2016 to 321 in 2019 (×10<sup>6</sup> inhabitants). Comorbidities measured by the age-adjusted Charlson Comorbidity Index ranged between 3.47 and 3.77 and increased over the period. The in-hospital complications have remained constant over the years with some exceptions. Death rate (×10<sup>6</sup> inhabitants) was 18.0, and the in-hospital mortality per year range was statistically constant and between 5.23% and 6.20%. The unadjusted LoS ranged from 14.68 to 15.34 days (standard deviations [SD], 16.03 and 15.79) including 2.68 to 3.27 days (SD, 6.57–7.82) in the intensive care unit. VHD procedures costs amounted to €1403.13 million in the period, representing an annual cost of €350.8 million. These costs decreased by 3.17% over the period. Per-procedure mean cost also decreased from €24801.81 (SD, €10231.91) to €24015.50 (SD, €9825.39).</div></div><div><h3>Conclusions</h3><div>VHD entails a large and increasing volume of procedures in Spain. While a decline in the per-procedure mean cost was noted, the overall annual cost increased. This underscores the substantial burden on the national health system, even when considering solely in-hospital procedures.</div></div>","PeriodicalId":36870,"journal":{"name":"REC: CardioClinics","volume":"59 4","pages":"Pages 285-294"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140276223","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Determinación de la lipoproteína (a) y prevalencia de valores elevados entre los asistentes a una reunión científica 脂蛋白（a）的测定和科学会议与会者中脂蛋白（a）值升高的流行率

REC: CardioClinics Pub Date : 2024-10-01 DOI: 10.1016/j.rccl.2024.06.001

Rosa Fernández Olmo , Armando Oterino , Miriam Martín Toro , Javier Mora , Mario Baquero , Alberto Cordero

引用次数: 0